Drugs / rVSV∆G-ZEBOV-GP vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02788227 | Oct 2016 → Jun 2025 | — | National Institutes of Health Clinical Center (CC) | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rVSV∆G-ZEBOV-GP vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02788227 ↗ |
| Known as | V920 | “This protocol is a multi-center study to evaluate the durability of the immune response following the open label administration of the rVSV∆G-ZEBOV-GP vaccine (V920) as...” NCT02788227 ↗ |
| Modality | Vaccine | “rVSV∆G-ZEBOV-GP vaccine also known as V920” NCT02788227 ↗ |
| Route | Intramuscular | “1ml intramuscular injection in the deltoid muscle” NCT02788227 ↗ |